U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile
September 03 2020 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the U.S. Department of Health and Human Services (HHS) has
exercised its option to purchase an additional 10,000 doses of
BioCryst’s approved antiviral influenza therapy,
RAPIVAB
® (peramivir injection), for approximately
$7 million.
The RAPIVAB purchase by the HHS Office of the
Assistant Secretary for Preparedness and Response will supply the
Strategic National Stockpile (SNS), the nation’s largest supply of
life-saving pharmaceuticals and medical supplies for use in a
public health emergency.
“There is great concern for the potential impact
on the healthcare system in general, and hospitals in particular,
of the upcoming influenza season in the midst of the COVID-19
pandemic. RAPIVAB is an important antiviral with proven benefits
for influenza patients, and we appreciate the opportunity to
deliver more RAPIVAB to the SNS to hold as a supplement for public
health authorities and healthcare facilitites that might need it at
this critical time,” said Jon Stonehouse, chief executive officer
of BioCryst.
The order is part of a $34.7 million contract
(Contract No. 75D301-18-C-02984) the Centers for Disease Control
and Prevention awarded in 2018 for the procurement of up to 50,000
doses of RAPIVAB (peramivir injection) over a
five-year period for the SNS.
About RAPIVAB (peramivir
injection)RAPIVAB (peramivir injection) is approved in the
United States for the treatment of acute uncomplicated influenza in
patients 2 years and older who have been symptomatic for no more
than two days. It is administered via an intravenous infusion for a
minimum of 15 minutes at recommended doses of 600 mg/kg for adults
and adolescents and 12 mg/kg for pediatric patients ages 2 to 12
years. Efficacy of RAPIVAB is based on clinical trials of naturally
occurring influenza in which the predominant influenza infections
were influenza A virus and a limited number of patients infected
with influenza B virus. Visit http://www.rapivab.com to learn
more.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. BioCryst has several ongoing
development programs including ORLADEYO™ (berotralstat), an oral
treatment for hereditary angioedema, BCX9930, an oral Factor D
inhibitor for the treatment of complement-mediated diseases,
galidesivir, a potential treatment for COVID-19, Marburg virus
disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
Forward Looking Statements
This press release contains forward-looking
statements, including statements regarding sales of RAPIVAB. These
statements involve known and unknown risks, uncertainties and other
factors which may cause BioCryst’s actual sales to be materially
different from those expressed or implied by the forward-looking
statements. These statements reflect our current views with respect
to future events and are based on assumptions and are subject to
risks and uncertainties. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Some of
the factors that could affect the forward-looking statements
contained herein include: the U.S. government may purchase smaller
quantities of RAPIVAB than currently anticipated, or none at all;
BioCryst relies on third-party manufacturers to manufacture RAPIVAB
in a timely manner and in accordance with applicable governmental
regulations, and any failure of such third-party manufacturers to
perform their obligations could impact BioCryst’s ability to supply
RAPIVAB pursuant to the government contract; government
contracts contain certain terms and conditions, including
termination provisions, that subject BioCryst to additional risks;
and the ongoing COVID-19 pandemic, which could create challenges in
all aspects of BioCryst’s business, including without limitation
delays, stoppages, difficulties, and increased expenses with
respect to BioCryst’s and its partners’ supply chains, negatively
impact BioCryst’s ability to access the capital or credit markets
to finance its operations, or have the effect of heightening the
other risks described herein or in the documents BioCryst files
periodically with the Securities and Exchange Commission. Please
refer to the documents BioCryst files periodically with the
Securities and Exchange Commission, specifically BioCryst’s most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
and Current Reports on Form 8-K, which identify important factors
that could cause the actual results to differ materially from those
contained in BioCryst’s forward-looking statements.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024